Search results
Results from the WOW.Com Content Network
The Brazilian Nonproprietary Name or DCB, from the Portuguese Denominação Comum Brasileira is the official Portuguese nomenclature for drugs or active ingredients that have been approved by the Brazilian Health Regulatory Agency (ANVISA) for use in Brazil. [1] [2] The consolidated list from October 2021 contains just over 12,300 items. [3]
Immunosuppressive drugs: Prescription notification form, and a consent form regarding teratogenic risks, confirming understanding and agreeing to be the sole user of the drug. (form provided by a local public health organization to the doctor) [5] C4 Antiretroviral drugs: management of HIV/AIDS - List revoked in September 2016. [6] revoked C5
COVID-19: Shionogi: 3C-like protease inhibitor Entecavir: HIV NRTI 2005 Etravirine (Intelence) [8] HIV NNRTI 2008 Famciclovir: Herpes Zoster: Guanosine analogue 1994 Fomivirsen: AIDS Anti-sense oligonucleotide: Anti-sense FDA-licensed in 1998; Withdrawn in EU (2002), US (2006) Fosamprenavir: HIV ViiV Healthcare: Amprenavir pro-drug: 2003 (FDA ...
Brazil is now the country with the third-most coronavirus cases in the world. Before, chloroquine and hydroxychloroquine were reserved for only severe cases. Brazil Allows Anti-Malarial Drug For ...
Brazil's doctors are calling for stricter measures as the daily coronavirus death toll shows little sign of easing — while the nation’s turbulent politics threaten to undermine efforts to ...
In March 2020, then US President Donald Trump promoted the use of chloroquine and hydroxychloroquine, two related anti-malarial drugs, for treating COVID-19. The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19.
Brazil's coronavirus outbreak worsened on Wednesday and the South American nation could soon have the second-highest number of cases in the world as the Health Ministry reported 888 new deaths and ...
The trial led by Cadegiani looked at the experimental prostate cancer and antiandrogen proxalutamide, and people from the Brazilian region of Amazon were recruited as patients in the study, given the surge in Covid-19 cases in that region in the early months of the COVID-19 pandemic in Brazil which would, according to the study's author, favor ...